Influence of Physical Activity Intervention on Circulating Soluble Receptor for Advanced Glycation end Products in Elderly Subjects by Kotani, Kazuhiko et al.
Short Communication J Clin Med Res  •  2011;3(5):252-257
ress Elmer 
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press™   |   www.jocmr.org
Inﬂ  uence of Physical Activity Intervention on Circulating 
Soluble Receptor for Advanced Glycation end 
Products in Elderly Subjects
Kazuhiko Kotania, b, c, d, Russell Caccavellob, Naoki Sakanec, Toshiyuki Yamadaa, 
Nobuyuki Taniguchia, Alejandro Gugliuccib
Abstract
Background: Inﬂ   ammation, often accompanied by oxidation, 
caused by advanced glycation end products (AGEs) may be 
quenched by the soluble receptor for AGEs (sRAGE).  The pres-
ent study aimed to investigate the inﬂ  uence of physical activity on 
circulating sRAGE, and the association between changes of circu-
lating sRAGE and paraoxonase1 (PON1) activity (as an antioxida-
tive enzyme) in a physical activity intervention study on an elderly 
subject cohort.
Methods: Serum sRAGE, PON1 activity and cardiometabolic 
variables were measured in 30 community-dwelling asymptomatic 
Japanese volunteers (15 men/15 women, mean age 65 years) in the 
pre- and post-phase of a 6-month interventional program designed 
to increase physical activity.
Results: The body mass index and sRAGE levels (1103 ± 496 to 
1030 ± 437 ng/L, P < 0.05) were signiﬁ  cantly reduced during the 
intervention period. In addition, the change of sRAGE was signiﬁ  -
cantly and inversely correlated with that of PON1 activity, indepen-
dent of the other cardiometabolic variables (β = - 0.511, P < 0.01).
Conclusions: This study showed a reduction of sRAGE levels, and 
an inverse correlation between sRAGE and PON1 activity, after the 
intervention study increasing physical activity on an elderly popu-
lation. These ﬁ  ndings represent a modest but signiﬁ  cant modulation 
of sRAGE by this type of exercise intervention, which warranted 
future studies on the clinical relevance of sRAGE changes in physi-
cal activity.
Keywords: AGEs; RAGE; Paraoxonase1; Exercise; Atherosclero-
sis
Introduction
Advanced glycation end products (AGEs), a heterogeneous 
group of adducts formed on proteins, lipids and nucleotides 
and by reactive carbonyls, are generated under conditions of 
hyperglycemia and oxidative stress or a combination of both 
(e.g., glucose intolerance, renal failure and chronic inﬂ  am-
matory disorders) [1, 2]. The sustained high levels of AGEs 
activates the expression of the receptor for AGEs (RAGE), 
which is a multiligand member of the immunoglobulin su-
perfamily of cell surface molecules [3-5].  The engagement 
of RAGE with AGEs (as one class of RAGE ligands) has 
been implicated in the development of various disorders 
including vascular disease [2-5].  RAGE has a C-truncated 
secretory isoform of the receptor protein, termed soluble 
RAGE (sRAGE), and endogenous sRAGE has recently been 
identiﬁ  ed in humans [2-5].  Soluble RAGE is postulated to 
play an antagonistic role by competing with the cell surface 
receptor, thus preventing the adverse effects of RAGE-sig-
naling (namely, nuclear factor-kappa B-mediated RAGE-
elicited damage) [2-5]. Indeed, one study reported an inverse 
relationship between circulating sRAGE levels and cardio-
metabolic markers in the general population, suggesting that 
sRAGE levels, as a decoy of AGE, may increase and serve as 
protective players in common lifestyle-related diseases [6].   
On the other hand, another study reported a positive correla-
tion between circulating sRAGE levels and microvascular 
dysfunction and diabetic nephropathy, suggesting sRAGE 
may increase as a marker reﬂ  ective of a proinﬂ  ammatory 
state [7]. Thus, many remains to be explored to ascertain the 
physiological function of endogenous sRAGE, and there is 
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a paucity of information on the regulation of sRAGE levels.
While increases in physical activity and exercise are 
widely purported to maintain health and minimize or prevent 
several diseases, functional loss as well as disability, and 
are essential to healthy ageing in older people, the underly-
ing mechanisms have been incompletely elucidated [8-10]. 
Although only one study on exercise has shown a non-sig-
niﬁ  cant change of circulating sRAGE levels in both coro-
nary artery disease patients and healthy subjects, this was 
based on a speciﬁ  c study setting of a single bout of bicycle-
stressed exercise test [11]. As for the beneﬁ  cial health effects 
of physical activity, the antioxidant function of high-density 
lipoprotein (HDL) has received considerable attention [8-
10]. While paraoxonase1 (PON1) is a key antioxidative en-
zyme in HDL, we have previously shown and others have 
conﬁ  rmed that circulating AGEs can reduce PON1 activity 
[12, 13]. However, there are no reports on the association be-
tween sRAGE and PON1. Keeping this background in mind, 
the present intervention study in a cohort of healthy elderly 
subjects had the following aims: (1) to investigate the inﬂ  u-
ence of physical activity increase on circulating sRAGE, and 
(2) to observe the association between changes of circulating 
sRAGE and PON1 activity during an intervention period of 
increased physical activity.
Subjects and Methods
A total of 30 community-dwelling Japanese elderly volun-
teers (15 men/15 women; mean age = 65 ± 3 years) were 
recruited into a 6-month interventional program. All par-
ticipants were in good health, not current smokers, not on 
any medication and had not been diagnosed to have diabetes 
mellitus nor cardiovascular, liver, kidney, nutritional or col-
lagen diseases. The participants were sedentary (no habits of 
structured exercise < 30 minutes, twice a week). The present 
program, which focused on a mild-to-moderate increase in 
physical activity, included monthly explanatory and moti-
vational sessions to increase physical activity such as daily 
walking and to instruct on the appropriate methods. In par-
ticular, the participants were educated on how to measure 
their heart rates during a walking exercise in their radial ar-
terial pulses, and recommended to perform the walking at 
60% of the maximal heart rate of each individual and at least 
≥ 30 minutes. The study was approved by the Jichi Medi-
cal University ethics committee, and each subject provided 
informed consent.
In the pre- and post-phase of this intervention, cardio-
metabolic variables were measured during an overnight 
fasted state in all subjects. Body mass index (BMI) was 
Table 1. Clinical Characteristics in the Pre- to Post-phase of Intervention
Variable Pre-phase Post-phase P value
Body mass index, kg/m2 23.6 ± 2.4 23.4 ± 2.5 0.018*
Systolic blood pressure, mmHg 137.1 ± 17.1 136.9 ± 21.1 0.948
Diastolic blood pressure, mmHg 78.6 ± 11.5 79.8 ± 11.5 0.336
LDL-cholesterol, mmol/L 3.47 ± 0.71 3.28 ± 0.70 0.072
Triglycerides, mmol/L 1.19 (0.80-1.43) 1.14 (0.83-1.47) 0.502
HDL-cholesterol, mmol/L 1.83 ± 0.39 1.83 ± 0.39 0.883
Fasting plasma glucose, mmol/L 5.33 ± 0.53 5.25 ± 0.58 0.386
Insulin, μU/mL 4.5 (3.7-6.8) 5.0 (3.7-6.2) 0.749
HOMA-IR 1.15 (0.80-1.62) 1.20 (0.88-1.40) 0.626
PON1, U/L 161.3 ± 49.5 160.6 ± 50.0 0.870
Soluble RAGE, ng/L   1103 ± 496 1030 ± 437 0.019*
LDL: low-density lipoprotein; HDL: high-density lipoprotein; HOMA-IR: homeostasis model assessment of insu-
lin resistance; PON1: paraoxonase1; RAGE: the receptor for advanced glycation end products.
Data are expressed as the means ± standard deviations or the medians (interquartile ranges).
Signiﬁ  cance level (difference between the pre- and post-phase data by a paired t-test [triglycerides, insulin and 
HOMA-IR were log-transformed]): *P < 0.05.
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calculated as the weight divided by the square of the height 
measured in light indoor clothing without shoes. Systolic 
blood pressure (SBP) and diastolic blood pressure (DBP) 
was determined in the right arm of each subject in the seated 
position after a 5-minute rest, using the sphygmomanometer. 
Serum low-density lipoprotein cholesterol and HDL choles-
terol (HDL-C) were determined using homogeneous meth-
ods, and serum triglycerides (TG) and plasma glucose were 
measured using enzymatic methods. Plasma insulin was 
measured using an enzyme immunoassay (TOSOH Co. Ltd., 
Tokyo, Japan), and the homeostasis model assessment of in-
sulin resistance (HOMA-IR) was calculated using a formula 
based on the plasma glucose and insulin levels, as described 
previously [14].
Serum PON1 activity was kinetically measured using 
paraoxone as a substrate, from the initial velocity of p-ni-
trophenol production at 37 °C, and recorded at 405 nm in a 
Versamax Microplate Reader (Molecular Diagnostics, CA, 
USA), as described previously [15, 16]. Serum sRAGEs 
were measured by an enzyme-linked immunosorbent assay 
using the Quantikine Human RAGE Immunoassay (R&D 
Systems Inc., Minneapolis, MN, USA). It contains NS0-
expressed recombinant human RAGE/Fc Chimera and has 
been shown to accurately quantitate the recombinant factor.   
Plates were read with a Versamax Microplate Reader (Mo-
lecular Diagnostics, CA, USA).
Data are shown as the mean ± standard deviation or 
the median plus interquartile ranges.  Paired t test was used 
to compare the pre- and post-phase values of respective 
measured variables. Single linear regression analysis and 
stepwise multiple linear regression analysis adjusted for 
measured variables were used to evaluate the correlations 
between the variables in the pre-phase as well as between 
the changes between the pre- and post-phase. The magnitude 
of the changes was calculated by subtracting the pre-phase 
values from the post-phase values in each case. The vari-
Table 2. Correlations of Soluble RAGE With Other Variables
RAGE: the receptor for advanced glycation end product; LDL: low-density lipoprotein; HDL: high-density lipo-
protein; HOMA-IR: homeostasis model assessment of insulin resistance; PON1: paraoxonase1; Pre-phase: 
correlation between the pre-phase data in respective variables; Pre- and post-change: correlation between 
the level changes (the post-phase data minus the pre-phase data) in respective variables (age and gender 
used the pre-phase data were); r: simple linear regression coefﬁ  cient between soluble RAGE and another 
variable; β: multiple linear regression coefﬁ  cient in a stepwise multivariate analysis for soluble RAGE after 
controlling for all the listed variables (except for HOMA-IR).
Triglycerides, insulin and HOMA-IR were log-transformed for the analyses.
Signiﬁ  cance level: *P < 0.05; **P < 0.01.
Variable
Pre-phase Pre- and post-change
r (P value) r (P value)
Age, years 0.068 (0.722) 0.188 (0.318)
Gender, male -0.063 (0.742) 0.011 (0.955)
Body mass index, kg/m2 -0.512 (0.004)** -0.191 (0.313)
Systolic blood pressure, mmHg 0.048 (0.800) 0.135 (0.476)
Diastolic blood pressure, mmHg -0.071 (0.710) 0.174 (0.358)
LDL-cholesterol, mmol/L -0.080 (0.673) -0.230 (0.221)
Triglycerides, mmol/L -0.050 (0.792) 0.123 (0.516)
HDL-cholesterol, mmol/L -0.154 (0.418) -0.189 (0.317)
Fasting plasma glucose, mmol/L -0.021 (0.912) -0.030 (0.874)
Insulin, μU/mL -0.290 (0.120) 0.041 (0.829)
HOMA-IR -0.365 (0.047)* -0.013 (0.944)
PON1, UL -0.166 (0.381) -0.511 (0.004)**
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ables of TG, insulin and HOMA-IR were log-transformed 
in these analyses because of their skewed distribution.  Due 
to a close co-linearity of insulin and HOMA-IR (correlation 
coefﬁ  cient > 0.8), insulin (instead of HOMA-IR) was en-
tered into the stepwise multivariate model. A P value < 0.05 
was considered to be signiﬁ  cant.
Results
Clinical characteristics of the studied subjects are listed in 
Table 1. There was a modest but signiﬁ  cant reduction in 
BMI levels, and similarly, circulating sRAGE levels were 
signiﬁ  cantly reduced through the present intervention on 
physical activity. Small changes were observed in the other 
cardiometabolic variables including PON1 activity.
Univariate correlations between sRAGE and the other 
cardiometabolic variables are listed in Table 2. In the pre-
phase, sRAGE levels were signiﬁ  cantly and inversely corre-
lated with BMI and HOMA-IR, respectively. Subsequently, 
a stepwise multivariate analysis conﬁ  rmed BMI as the only 
independent, signiﬁ   cant and inverse variable for sRAGE 
(β = - 0.512, P = 0.004). Furthermore, in terms of the level 
changes between pre- and post-phase, the change of sRAGE 
levels was signiﬁ  cantly and inversely correlated with that of 
PON1 activity. A subsequent stepwise multivariate analysis 
conﬁ  rmed the change of PON1 as the only independent, sig-




The present study on asymptomatic elderly people showed 
two new ﬁ  ndings: (1) circulating sRAGE levels were sig-
niﬁ  cantly reduced during an interventional period of physi-
cal activity increase, and (2) an independent, signiﬁ  cant and 
inverse correlation between changes of circulating sRAGE 
and PON1 activity was observed during the intervention. 
Because the reduction of sRAGE concentrations was sig-
niﬁ  cant but modest, and the role of endogenous sRAGE, in 
comparison to that in experimental settings, is under scru-
tiny [7], the clinical relevance of the present study should be 
conﬁ  rmed in future studies. However, the present ﬁ  ndings 
showing a factor that modulates sRAGE concentrations are 
interesting, since sRAGE is considered an important bio-
marker of cardiometabolic pathophysiology and a possible 
therapeutic target on various disorders [2-5].
Contrasting our results on the change of sRAGE levels 
after the interventions, an earlier study has reported a non-
signiﬁ  cant (with a trend to increase) change of sRAGE levels 
after a single bout of bicycle-stress exercise [11]. Large dif-
ferences in the intervention methods and durations, as well 
as studied populations, make a simple comparison between 
the earlier study and ours difﬁ  cult. In addition, our interven-
tion was at a mild-to-moderate increase in physical activ-
ity that did not produce apparent changes in blood pressure, 
glucose or lipid panels; thus, these general cardiometabolic 
factors did not appear to be involved in the mechanisms of 
the observed reduction of sRAGE in the present popula-
tion. However, some previous work on lifestyle modiﬁ  ca-
tion may help to explain, in part, the potential mechanisms 
for the reduction of sRAGE. Although the present study did 
not measure AGEs, we have previously shown that a caloric 
restriction intervention signiﬁ  cantly reduces AGEs [16] and 
a 3-month physical activity intervention, like ours, report-
edly induced a signiﬁ  cant reduction of AGEs [17, 18].  The 
reduction of circulating AGEs can inactivate the expression 
of RAGE, thereby leading to the reduction of sRAGE as a 
decoy of AGEs [2-5]. This may be an adaptive response to 
increased physical activity in relatively healthy individuals. 
As another mechanistic explanation, the improvement of the 
sedentary status can attenuate inﬂ  ammation, thereby leading 
to the reduction of sRAGE as a marker reﬂ  ective of chronic 
inﬂ  ammation [7]. Finally, there may be an increase of the 
clearance of sRAGE from the circulation as a result of hemo-
dynamic changes induced by the increase in physical activity 
[3, 19].
Regarding the association between sRAGE and cardio-
metabolic variables including PON1 activity, an indepen-
dent, signiﬁ  cant and inverse correlation between sRAGE 
and BMI was observed in the pre-phase of the present study. 
This result is in agreement with earlier ﬁ  ndings, suggesting 
that sRAGE may be protective of cardiometabolic outcomes 
[6]. A novel result of our study is a clear inverse correla-
tion between changes of sRAGE and PON1 activity, even 
though the changes of PON1 activity were small during the 
intervention. Of interest, we have shown and others have 
conﬁ  rmed in a recent study that AGEs can reduce PON1 ac-
tivity [12, 13]. Given the prior ﬁ  ndings on AGEs [17, 18], a 
reduction of AGEs through physical activity (which can lead 
to an adaptive reduction of sRAGE as aforementioned) may 
restore PON1 activity. Despite an inverse but non-signiﬁ  cant 
correlation between sRAGE and PON1 in the pre-phase, the 
fact that a signiﬁ  cant correlation between changes of sRAGE 
and PON1 was observed during the intervention might also 
imply an individual difference in the response to physical 
activity increase, for instance, based on genetic components 
[20, 21]. RAGE binds to several ligand molecules, such as 
S100-calcium binding protein/calgranulins, high-mobili-
ty group protein 1, amyloid-β-peptides and the family of 
β-sheet ﬁ  brils, besides AGEs [2-4], so more studies includ-
ing these molecules are also warranted.
There are some limitations to our study. The sample size 
was relatively small. The intervention period was restricted 
to 6-month. The levels of sRAGE and PON1 activity can be 
affected by genetic and ethnic factors [19, 20]. Future studies 
with larger and ethnically diverse populations and/or longer 
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follow-up periods are necessary to expand the generizability 
of our results.
In summary, the present study found a signiﬁ  cant reduc-
tion of circulating sRAGE levels, and an independent, sig-
niﬁ  cant and inverse correlation between changes of circulat-
ing sRAGE and PON1 activity after a 6-month intervention 
to increase physical activity in asymptomatic elderly people. 
Further research is needed to conﬁ  rm the present ﬁ  ndings 
and explore the biological mechanisms of this association.
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